Full-Time

Head of Investor Relations/Executive Team Chief of Staff

Posted on 8/23/2026

Attovia

Attovia

51-200 employees

Clinical-stage biopharma developing biparatopic nanobodies

Compensation Overview

$265k - $315k/yr

San Carlos, CA, USA

In Person

Bachelor's, MBA

Category
Finance & Banking (1)
Required Skills
CRM
Mergers & Acquisitions (M&A)
Investment Banking

Get referred to Attovia

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 8 years of relevant experience in investor relations, equity research, investment banking, or corporate finance, including meaningful experience in biotech, pharma, or life sciences.
  • Strong understanding of financial reporting, valuation methodologies, and capital markets used by investment professionals.
  • Exceptional written and verbal communication skills, strong organization, meticulous attention to detail, and accuracy.
  • Ability to manage multiple priorities in a fast-paced, dynamic environment and deliver polished output under tight deadlines.
Responsibilities
  • Develop and execute a comprehensive investor relations strategy aligned with corporate objectives, pipeline milestones, and long-term growth ambitions.
  • Manage the company's current investor relations agency and future public relations/media agency.
  • Serve as the day-to-day point of contact for the buy-side and sell-side investment community, fielding inquiries and building relationships with current and prospective shareholders.
  • Partner with agencies to manage investor-facing materials, including press releases, earnings call scripts and Q&A preparation, investor presentations, media communications, fact sheets, and the annual report.
  • Partner with the executive team to prepare for and manage quarterly earnings calls, board meetings, investor conferences, medical conferences, non-deal roadshows, and R&D-day presentations.
  • Lead proactive and targeted investor outreach, including identifying and cultivating relationships with new institutional investors.
  • Monitor and analyze sell-side analyst research, market activity, shareholder composition, and peer and competitor developments, and deliver regular updates and insights to the executive team and Board.
  • Collaborate with R&D, clinical development, regulatory, legal, and corporate communications to ensure accurate, consistent, and compliant messaging across investor touchpoints.
  • Support corporate development activities, including materials related to M&A, partnerships, licensing deals, and capital markets transactions such as follow-on offerings.
  • Manage the corporate website, including its investor relations section.
  • Ensure compliance with SEC regulations, Regulation FD, and other disclosure requirements in coordination with Legal.
  • Build out and scale the investor relations function's tools, processes, and infrastructure as the company grows.
  • Attend and document minutes and key decisions at weekly Executive Committee meetings, follow up on decisions and action items, and work with the CEO and Executive Committee on corporate communications and special projects.
  • Assist the Executive Team with coordinating activities requiring cross-functional involvement through close partnership with the Program Management Team.
Desired Qualifications
  • An MBA, CFA, or advanced scientific degree is a plus.
  • Experience at a publicly traded biotech or pharmaceutical company, including direct experience supporting earnings calls, roadshows, and SEC reporting cycles, is strongly preferred.
  • Scientific fluency and comfort engaging with clinical and regulatory content, including translating complex science into an accessible investment narrative, especially in autoimmune diseases.
  • Experience with investor-relations-specific tools such as shareholder identification/CRM platforms and earnings call/webcast providers.
  • A proven track record building relationships and influencing across all levels of an organization, including senior executives and the Board.
  • Experience in a Chief of Staff or senior project management role.

Preparing company summary.

Company Size

51-200

Company Stage

IPO

Headquarters

Fremont, California

Founded

2023

Get referred to Attovia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Attovia priced its August 4, 2026 IPO at $17, raising $289 million.
  • The IPO plus cash supports operations into 2029, funding multiple clinical milestones.
  • Board additions on July 15, 2026 and strong demand signal institutional backing after listing.

What critics are saying

  • ATTO-1310 still faces human proof-of-concept risk; failure kills the platform story by 2027.
  • ATTO-2306 collides with Sanofi and Regeneron’s Dupixent, squeezing differentiation and pricing power.
  • Post-IPO expectations into 2029 depend on successful Phase 2 data; misses force dilution.

What makes Attovia unique

  • ATTOBODY’s biparatopic nanobodies attack two sites, targeting GPCRs and cytokines other biologics miss.
  • Attovia’s pipeline spans pruritus, atopic dermatitis, and IBD, not a single-disease story.
  • The Alamar worldwide license gives Attovia exclusive platform rights and proprietary engineering leverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

3%
wallstreet:online AG
Aug 5th, 2026
Attovia Therapeutics prices upsized $289M IPO at $17 per share

Attovia Therapeutics, a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases, priced its upsized initial public offering at $17.00 per share. The San Carlos-based company will sell 17,000,000 shares, generating gross proceeds of $289.0 million before underwriting costs and expenses. Attovia has also granted underwriters a 30-day option to purchase up to 2,550,000 additional shares at the offering price. The company's common stock is expected to begin trading on the Nasdaq Global Market on 5 August 2026 under the ticker symbol "ATTO", with the offering closing on 6 August 2026. Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets are serving as joint book-running managers, whilst LifeSci Capital acts as passive book-running manager.

AInvest Fintech Inc.
Jul 14th, 2026
Goldman Sachs and venBio hold 5%+ stakes in Attovia after $105M Series B

Attovia Therapeutics has disclosed that Venbio Global Strategic Fund IV and Goldman Sachs-affiliated entities each hold 5% or greater stakes in the company. This follows Attovia's oversubscribed $105 million Series B financing round, led by Goldman Sachs Alternatives with participation from venBio and other investors. Since launching in June 2023, Attovia has raised $165 million in total. The Series B proceeds will advance lead programmes ATTO-1310 and ATTO-002 through initial clinical readouts and further develop its ATTOBODY platform. Goldman Sachs Alternatives appointed Colin Walsh to Attovia's board of directors. VenBio has been a consistent investor since Attovia's inception. The increased ownership reflects investor confidence in Attovia's pipeline and proprietary platform for developing bi-specific therapeutics targeting immune-mediated diseases.

FinSMEs
Apr 16th, 2025
Attovia Therapeutics Raises $90M in Series C Financing

Attovia Therapeutics, a San Carlos, CA-based privately-held, clinical-stage biopharma company, raised $90M in Series C funding

Greenville Business Magazine
Apr 15th, 2025
Attovia secures $90M for ATTOBODY programs

Attovia Therapeutics announced a $90 million Series C financing led by Deep Track Capital, with participation from new and existing investors. The funds will advance clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and expand their pipeline of multi-specific therapeutic candidates. Rebecca Luse from Deep Track Capital will join the Board of Directors. The financing supports Attovia's goal of achieving clinical proof-of-concept for its lead assets.

BioSpace
May 9th, 2024
Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies

The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another for immune-mediated diseases.